What We're Reading
Rising Stars in Cancer Immunology
PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Peripheral neuropathy has been reported in the context of combination treatment with checkpoint inhibitors and chemotherapeutic agents. The authors show that PD-1/PD-L1 checkpoint inhibition can enhance paclitaxel-induced neuropathic pain by inhibiting neuroimmune PD-1/PD-L1 antinociceptive signaling.
Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors
The role of mammary tissue–associated mast cells during breast cancer is poorly defined. Here, the authors uncover a novel gut microbiome–mast cell axis in mammary tissue that enhances early metastatic spread of HR+ tumors.
The tumor microenvironment (TME) of clear cell ovarian cancer is characterized. Immune infiltration and collagen deposition differ based on disease stage, TME localization, and ARID1A status, highlighting the necessity of evaluating multiple features when determining treatment strategy.
A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
Two distinct populations of TIM4-expressing tumor-associated macrophages localize to tertiary lymphoid structures or body cavities and either promote T-cell responses or induce immunosuppression, respectively, suggesting novel treatment approaches and relevance for selection of immune therapy.
Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
CAR T cells targeting tumor-associated macrophages are found to stimulate IFNγ-dependent endogenous T cell–mediated antitumor activity in mouse models of solid tumors. CAR T cell depletion of macrophages shows promise as a strategy for tumor antigen–agnostic immunotherapy.
Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand–Expressing Solid Tumors
Tumors expressing FasL can kill antitumor T cells. The enhanced antitumor effects of CAR T cells armed with secreted Fas decoys reported here suggest a way to improve clinical efficacy of cellular therapies in solid tumors.
Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy
The mechanisms underlying hyperprogressive disease (HPD) associated with PD-1 blockade are unclear. The authors develop a way to reproduce HPD by partially eliminating CD8+ T cells with NIR-PIT, creating a regulatory T cell–dominant tumor microenvironment permissive of tumor growth.
ICBatlas: A Comprehensive Resource for Depicting Immune Checkpoint Blockade Therapy Characteristics from Transcriptome Profiles
ICBatlas provides search, browse, and visualization functions for integrated and reanalyzed results based on large-scale transcriptome data from immune checkpoint blockade (ICB)–treated patient samples. This resource serves as a one-stop solution for transcriptome data–related research on ICB therapy.
Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
Bone marrow T-cell clonal expansion, immune phenotypes, and specificities at the single-cell level were determined in treatment-naïve multiple myeloma. Dominant T-cell clones rarely recognize antigens presented on myeloma cells, are not neoantigen-specific, and show low immune checkpoint expression.